Christopher Yea

Corporate Officer/Principal at KALVISTA PHARMA

62 year

Health Technology

Consumer Services

Commercial Services

Profile

Christopher M.
Yea was the founder of Vantia Ltd. and held the title of Chief Operating Officer from 2008 to 2015.
Dr. Yea is currently the Chief Development Officer at KalVista Pharmaceuticals Ltd. since 2015 and at KalVista Pharmaceuticals, Inc. since 2016.
Education includes undergraduate and doctorate degrees from the University of Bristol.

Christopher Yea active positions

Companies	Position	Start
KALVISTA PHARMA	Corporate Officer/Principal	2016-10-31
KalVista Pharmaceuticals Ltd. KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops oral medicines	Corporate Officer/Principal	2015-10-31

All active positions of Christopher Yea

Former positions of Christopher Yea

Companies	Position	End
Vantia Ltd. Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Provides molecule agonists of vasopressin receptors	Founder	2015-10-31

See the detail of Christopher Yea's experience

Training of Christopher Yea

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Christopher Yea's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
University of Bristol University of Bristol Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Vantia Ltd. Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Provides molecule agonists of vasopressin receptors	Commercial Services
KalVista Pharmaceuticals Ltd. KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops oral medicines	Health Technology
KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets small molecule protease inhibitors for diseases	Health Technology